NCT05693142: An ongoing trial by Regenxbio Inc.
This trial is ongoing. It must report results 1 year, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05693142 |
|---|---|
| Title | A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males With Duchenne Muscular Dystrophy (DMD) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 4, 2023 |
| Completion date | Feb. 28, 2026 |
| Required reporting date | Feb. 28, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |